Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Temperate Prophages Increase Bacterial Adhesin Expression and Virulence in an Experimental Model of Endocarditis Due to Staphylococcus aureus From the CC398 Lineage.

Laumay F, Corvaglia AR, Diene SM, Girard M, Oechslin F, van der Mee-Marquet N, Entenza JM, François P.

Front Microbiol. 2019 Apr 24;10:742. doi: 10.3389/fmicb.2019.00742. eCollection 2019.

2.

Marginal role of von Willebrand factor-binding protein and coagulase in the initiation of endocarditis in rats with catheter-induced aortic vegetations.

Mancini S, Oechslin F, Menzi C, Que YA, Claes J, Heying R, Veloso TR, Vanassche T, Missiakas D, Schneewind O, Moreillon P, Entenza JM.

Virulence. 2018;9(1):1615-1624. doi: 10.1080/21505594.2018.1528845.

3.

Solar photo-Fenton disinfection of 11 antibiotic-resistant bacteria (ARB) and elimination of representative AR genes. Evidence that antibiotic resistance does not imply resistance to oxidative treatment.

Giannakis S, Le TM, Entenza JM, Pulgarin C.

Water Res. 2018 Oct 15;143:334-345. doi: 10.1016/j.watres.2018.06.062. Epub 2018 Jun 26.

PMID:
29986243
4.

Assessment of the Dual Role of Clumping Factor A in S. Aureus Adhesion to Endothelium in Absence and Presence of Plasma.

Claes J, Ditkowski B, Liesenborghs L, Veloso TR, Entenza JM, Moreillon P, Vanassche T, Verhamme P, Hoylaerts MF, Heying R.

Thromb Haemost. 2018 Jul;118(7):1230-1241. doi: 10.1055/s-0038-1660435. Epub 2018 Jun 17.

PMID:
29909601
5.

In vitro characterization of PlyE146, a novel phage lysin that targets Gram-negative bacteria.

Larpin Y, Oechslin F, Moreillon P, Resch G, Entenza JM, Mancini S.

PLoS One. 2018 Feb 6;13(2):e0192507. doi: 10.1371/journal.pone.0192507. eCollection 2018.

6.

Fungicidal activity of copper-sputtered flexible surfaces under dark and actinic light against azole-resistant Candida albicans and Candida glabrata.

Ballo MKS, Rtimi S, Kiwi J, Pulgarin C, Entenza JM, Bizzini A.

J Photochem Photobiol B. 2017 Sep;174:229-234. doi: 10.1016/j.jphotobiol.2017.07.030. Epub 2017 Jul 29.

PMID:
28802173
7.

Clumping factor A, von Willebrand factor-binding protein and von Willebrand factor anchor Staphylococcus aureus to the vessel wall.

Claes J, Liesenborghs L, Peetermans M, Veloso TR, Missiakas D, Schneewind O, Mancini S, Entenza JM, Hoylaerts MF, Heying R, Verhamme P, Vanassche T.

J Thromb Haemost. 2017 May;15(5):1009-1019. doi: 10.1111/jth.13653. Epub 2017 Mar 23.

8.

Synergistic Interaction Between Phage Therapy and Antibiotics Clears Pseudomonas Aeruginosa Infection in Endocarditis and Reduces Virulence.

Oechslin F, Piccardi P, Mancini S, Gabard J, Moreillon P, Entenza JM, Resch G, Que YA.

J Infect Dis. 2017 Mar 1;215(5):703-712. doi: 10.1093/infdis/jiw632.

9.

Antibodies Targeting Hsa and PadA Prevent Platelet Aggregation and Protect Rats against Experimental Endocarditis Induced by Streptococcus gordonii.

Mancini S, Menzi C, Oechslin F, Moreillon P, Entenza JM.

Infect Immun. 2016 Nov 18;84(12):3557-3563. Print 2016 Dec.

10.

Comparative Genomics Analysis of Streptococcus tigurinus Strains Identifies Genetic Elements Specifically and Uniquely Present in Highly Virulent Strains.

Diene SM, François P, Zbinden A, Entenza JM, Resch G.

PLoS One. 2016 Aug 9;11(8):e0160554. doi: 10.1371/journal.pone.0160554. eCollection 2016.

11.

In Vitro and In Vivo Effectiveness of an Innovative Silver-Copper Nanoparticle Coating of Catheters To Prevent Methicillin-Resistant Staphylococcus aureus Infection.

Ballo MK, Rtimi S, Pulgarin C, Hopf N, Berthet A, Kiwi J, Moreillon P, Entenza JM, Bizzini A.

Antimicrob Agents Chemother. 2016 Aug 22;60(9):5349-56. doi: 10.1128/AAC.00959-16. Print 2016 Sep.

12.

Development of Potent and Selective S. aureus Sortase A Inhibitors Based on Peptide Macrocycles.

Rentero Rebollo I, McCallin S, Bertoldo D, Entenza JM, Moreillon P, Heinis C.

ACS Med Chem Lett. 2016 Apr 14;7(6):606-11. doi: 10.1021/acsmedchemlett.6b00045. eCollection 2016 Jun 9.

13.

Bactericidal activity and mechanism of action of copper-sputtered flexible surfaces against multidrug-resistant pathogens.

Ballo MK, Rtimi S, Mancini S, Kiwi J, Pulgarin C, Entenza JM, Bizzini A.

Appl Microbiol Biotechnol. 2016 Jul;100(13):5945-53. doi: 10.1007/s00253-016-7450-7. Epub 2016 Mar 28.

PMID:
27020284
14.

Fosfomycin plus β-Lactams as Synergistic Bactericidal Combinations for Experimental Endocarditis Due to Methicillin-Resistant and Glycopeptide-Intermediate Staphylococcus aureus.

del Río A, García-de-la-Mària C, Entenza JM, Gasch O, Armero Y, Soy D, Mestres CA, Pericás JM, Falces C, Ninot S, Almela M, Cervera C, Gatell JM, Moreno A, Moreillon P, Marco F, Miró JM; Hospital Clinic Experimental Endocarditis Study Group.

Antimicrob Agents Chemother. 2015 Nov 2;60(1):478-86. doi: 10.1128/AAC.02139-15. Print 2016 Jan.

15.

Aspirin plus ticlopidine prevented experimental endocarditis due to Enterococcus faecalis and Streptococcus gallolyticus.

Veloso TR, Oechslin F, Que YA, Moreillon P, Entenza JM, Mancini S.

Pathog Dis. 2015 Nov;73(8):ftv060. doi: 10.1093/femspd/ftv060. Epub 2015 Aug 26.

16.

Vaccination against Staphylococcus aureus experimental endocarditis using recombinant Lactococcus lactis expressing ClfA or FnbpA.

Veloso TR, Mancini S, Giddey M, Vouillamoz J, Que YA, Moreillon P, Entenza JM.

Vaccine. 2015 Jul 9;33(30):3512-7. doi: 10.1016/j.vaccine.2015.05.060. Epub 2015 Jun 3.

PMID:
26048778
17.

Reply to Eisen and McBryde.

Veloso TR, Que YA, Moreillon P, Entenza JM.

J Infect Dis. 2015 Aug 15;212(4):674-5. doi: 10.1093/infdis/jiv133. Epub 2015 Mar 9. No abstract available.

PMID:
25754979
18.

In vivo effect of flucloxacillin in experimental endocarditis caused by mecC-positive staphylococcus aureus showing temperature-dependent susceptibility in vitro.

Mancini S, Laurent F, Veloso TR, Giddey M, Vouillamoz J, Vandenesch F, Moreillon P, Entenza JM.

Antimicrob Agents Chemother. 2015 Apr;59(4):2435-8. doi: 10.1128/AAC.04733-14. Epub 2015 Jan 20.

19.

Assessment of the in vitro synergy of daptomycin plus linezolid against multidrug-resistant enterococci.

Entenza JM, Giddey M, Vouillamoz J, Moreillon P, Mancini S.

J Glob Antimicrob Resist. 2014 Dec;2(4):306-308. doi: 10.1016/j.jgar.2014.09.004. Epub 2014 Oct 2.

PMID:
27873692
20.

Prophylaxis of experimental endocarditis with antiplatelet and antithrombin agents: a role for long-term prevention of infective endocarditis in humans?

Veloso TR, Que YA, Chaouch A, Giddey M, Vouillamoz J, Rousson V, Moreillon P, Entenza JM.

J Infect Dis. 2015 Jan 1;211(1):72-9. doi: 10.1093/infdis/jiu426. Epub 2014 Aug 1.

PMID:
25086177
21.

Rapid detection of Staphylococcus aureus strains with reduced susceptibility to vancomycin by isothermal microcalorimetry.

Entenza JM, Bétrisey B, Manuel O, Giddey M, Sakwinska O, Laurent F, Bizzini A.

J Clin Microbiol. 2014 Jan;52(1):180-6. doi: 10.1128/JCM.01820-13. Epub 2013 Nov 6.

22.

Bactericidal synergism between daptomycin and the phage lysin Cpl-1 in a mouse model of pneumococcal bacteraemia.

Vouillamoz J, Entenza JM, Giddey M, Fischetti VA, Moreillon P, Resch G.

Int J Antimicrob Agents. 2013 Nov;42(5):416-21. doi: 10.1016/j.ijantimicag.2013.06.020. Epub 2013 Aug 9.

PMID:
23992647
23.

Streptococcus tigurinus is highly virulent in a rat model of experimental endocarditis.

Veloso TR, Zbinden A, Andreoni F, Giddey M, Vouillamoz J, Moreillon P, Zinkernagel AS, Entenza JM.

Int J Med Microbiol. 2013 Dec;303(8):498-504. doi: 10.1016/j.ijmm.2013.06.006. Epub 2013 Jun 20.

PMID:
23856340
24.

Use of a human-like low-grade bacteremia model of experimental endocarditis to study the role of Staphylococcus aureus adhesins and platelet aggregation in early endocarditis.

Veloso TR, Chaouch A, Roger T, Giddey M, Vouillamoz J, Majcherczyk P, Que YA, Rousson V, Moreillon P, Entenza JM.

Infect Immun. 2013 Mar;81(3):697-703. doi: 10.1128/IAI.01030-12. Epub 2012 Dec 17.

25.

Daptomycin for highly resistant Enterococcus faecium infection.

Rosin C, Bernsmeier C, Entenza JM, Moreillon P, Frei R, Weisser M, Flückiger U.

Swiss Med Wkly. 2012 Jun 26;142:w13603. doi: 10.4414/smw.2012.13603. eCollection 2012.

26.

High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis.

Miró JM, Entenza JM, Del Río A, Velasco M, Castañeda X, Garcia de la Mària C, Giddey M, Armero Y, Pericàs JM, Cervera C, Mestres CA, Almela M, Falces C, Marco F, Moreillon P, Moreno A; Hospital Clinic Experimental Endocarditis Study Group.

Antimicrob Agents Chemother. 2012 Aug;56(8):4511-5. Epub 2012 May 29.

27.

Vancomycin-intermediate Staphylococcus aureus selected during vancomycin therapy of experimental endocarditis are not detected by culture-based diagnostic procedures and persist after treatment arrest.

Moreillon P, Bizzini A, Giddey M, Vouillamoz J, Entenza JM.

J Antimicrob Chemother. 2012 Mar;67(3):652-60. doi: 10.1093/jac/dkr521. Epub 2011 Dec 13.

PMID:
22167243
28.

Molecular characterization of a Streptococcus gallolyticus genomic island encoding a pilus involved in endocarditis.

Danne C, Entenza JM, Mallet A, Briandet R, Débarbouillé M, Nato F, Glaser P, Jouvion G, Moreillon P, Trieu-Cuot P, Dramsi S.

J Infect Dis. 2011 Dec 15;204(12):1960-70. doi: 10.1093/infdis/jir666. Epub 2011 Oct 31.

PMID:
22043018
29.

Continuous infusion may improve the efficacy of vancomycin in treatment of experimental endocarditis due to heterogeneous vancomycin-intermediate Staphylococcus aureus.

Pea F, Cojutti P, Petrosillo N, Furlanut M, Entenza JM, Veloso TR, Vouillamoz J, Giddey M, Moreillon P.

Antimicrob Agents Chemother. 2011 Sep;55(9):4496; author reply 4496-7. doi: 10.1128/AAC.00603-11. No abstract available.

30.

In vivo synergism of ceftobiprole and vancomycin against experimental endocarditis due to vancomycin-intermediate Staphylococcus aureus.

Entenza JM, Veloso TR, Vouillamoz J, Giddey M, Majcherczyk P, Moreillon P.

Antimicrob Agents Chemother. 2011 Sep;55(9):3977-84. doi: 10.1128/AAC.00402-11. Epub 2011 Jul 5.

31.

Induction of experimental endocarditis by continuous low-grade bacteremia mimicking spontaneous bacteremia in humans.

Veloso TR, Amiguet M, Rousson V, Giddey M, Vouillamoz J, Moreillon P, Entenza JM.

Infect Immun. 2011 May;79(5):2006-11. doi: 10.1128/IAI.01208-10. Epub 2011 Feb 14.

32.

Failure of vancomycin continuous infusion against experimental endocarditis due to vancomycin-intermediate Staphylococcus aureus.

Entenza JM, Veloso TR, Vouillamoz J, Giddey M, Moreillon P.

Antimicrob Agents Chemother. 2011 Jan;55(1):385-7. doi: 10.1128/AAC.00811-10. Epub 2010 Oct 18.

33.

Role of MyD88 and Toll-like receptors 2 and 4 in the sensing of Parachlamydia acanthamoebae.

Roger T, Casson N, Croxatto A, Entenza JM, Pusztaszeri M, Akira S, Reymond MK, Le Roy D, Calandra T, Greub G.

Infect Immun. 2010 Dec;78(12):5195-201. doi: 10.1128/IAI.00786-10. Epub 2010 Sep 13.

34.

In vitro prevention of the emergence of daptomycin resistance in Staphylococcus aureus and enterococci following combination with amoxicillin/clavulanic acid or ampicillin.

Entenza JM, Giddey M, Vouillamoz J, Moreillon P.

Int J Antimicrob Agents. 2010 May;35(5):451-6. doi: 10.1016/j.ijantimicag.2009.12.022. Epub 2010 Feb 24.

PMID:
20185277
35.

Natural variability of in vitro adherence to fibrinogen and fibronectin does not correlate with in vivo infectivity of Staphylococcus aureus.

Ythier M, Entenza JM, Bille J, Vandenesch F, Bes M, Moreillon P, Sakwinska O.

Infect Immun. 2010 Apr;78(4):1711-6. doi: 10.1128/IAI.01274-09. Epub 2010 Jan 11.

36.

A single mutation in enzyme I of the sugar phosphotransferase system confers penicillin tolerance to Streptococcus gordonii.

Bizzini A, Entenza JM, Michielin O, Arnold I, Erni B, Moreillon P.

Antimicrob Agents Chemother. 2010 Jan;54(1):259-66. doi: 10.1128/AAC.00699-09. Epub 2009 Oct 26.

37.

Efficacy of iclaprim against wild-type and thymidine kinase-deficient methicillin-resistant Staphylococcus aureus isolates in an in vitro fibrin clot model.

Entenza JM, Haldimann A, Giddey M, Lociuro S, Hawser S, Moreillon P.

Antimicrob Agents Chemother. 2009 Sep;53(9):3635-41. doi: 10.1128/AAC.00325-09. Epub 2009 Jun 29.

38.

Tissue microarray and immunohistochemistry as tools for evaluation of antibodies against Chlamydia-like bacteria.

Borel N, Casson N, Entenza JM, Kaiser C, Pospischil A, Greub G.

J Med Microbiol. 2009 Jul;58(Pt 7):863-6. doi: 10.1099/jmm.0.009159-0. Epub 2009 Jun 4.

PMID:
19498205
39.

MsrR contributes to cell surface characteristics and virulence in Staphylococcus aureus.

Hübscher J, McCallum N, Sifri CD, Majcherczyk PA, Entenza JM, Heusser R, Berger-Bächi B, Stutzmann Meier P.

FEMS Microbiol Lett. 2009 Jun;295(2):251-60. doi: 10.1111/j.1574-6968.2009.01603.x. Epub 2009 May 1.

40.

Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies.

Entenza JM, Moreillon P.

Int J Antimicrob Agents. 2009 Jul;34(1):8.e1-9. doi: 10.1016/j.ijantimicag.2008.11.006. Epub 2009 Jan 21. Review.

PMID:
19162449
41.

Development of glycopeptide-intermediate resistance by Staphylococcus aureus leads to attenuated infectivity in a rat model of endocarditis.

Majcherczyk PA, Barblan JL, Moreillon P, Entenza JM.

Microb Pathog. 2008 Nov-Dec;45(5-6):408-14. doi: 10.1016/j.micpath.2008.09.003. Epub 2008 Sep 27.

PMID:
18930804
42.

The fibrinogen- and fibronectin-binding domains of Staphylococcus aureus fibronectin-binding protein A synergistically promote endothelial invasion and experimental endocarditis.

Piroth L, Que YA, Widmer E, Panchaud A, Piu S, Entenza JM, Moreillon P.

Infect Immun. 2008 Aug;76(8):3824-31. doi: 10.1128/IAI.00405-08. Epub 2008 Jun 9.

43.

Murine model of pneumonia caused by Parachlamydia acanthamoebae.

Casson N, Entenza JM, Borel N, Pospischil A, Greub G.

Microb Pathog. 2008 Aug;45(2):92-7. doi: 10.1016/j.micpath.2008.04.003. Epub 2008 Apr 18.

PMID:
18502092
44.

In vitro activities of tigecycline combined with other antimicrobials against multiresistant gram-positive and gram-negative pathogens.

Vouillamoz J, Moreillon P, Giddey M, Entenza JM.

J Antimicrob Chemother. 2008 Feb;61(2):371-4. Epub 2007 Nov 22.

PMID:
18033780
45.

Infectivity of Lactobacillus rhamnosus and Lactobacillus paracasei isolates in a rat model of experimental endocarditis.

Vankerckhoven V, Moreillon P, Piu S, Giddey M, Huys G, Vancanneyt M, Goossens H, Entenza JM.

J Med Microbiol. 2007 Aug;56(Pt 8):1017-24.

PMID:
17644707
46.

Single-dose oral amoxicillin or linezolid for prophylaxis of experimental endocarditis due to vancomycin-susceptible and vancomycin-resistant Enterococcus faecalis.

Moreillon P, Wilson WR, Leclercq R, Entenza JM.

Antimicrob Agents Chemother. 2007 May;51(5):1661-5. Epub 2007 Mar 12.

47.

Loss of penicillin tolerance by inactivating the carbon catabolite repression determinant CcpA in Streptococcus gordonii.

Bizzini A, Entenza JM, Moreillon P.

J Antimicrob Chemother. 2007 Apr;59(4):607-15. Epub 2007 Feb 27.

PMID:
17327292
48.

Effects of alpha-phosphoglucomutase deficiency on cell wall properties and fitness in Streptococcus gordonii.

Bizzini A, Majcherczyk P, Beggah-Möller S, Soldo B, Entenza JM, Gaillard M, Moreillon P, Lazarevic V.

Microbiology. 2007 Feb;153(Pt 2):490-8.

PMID:
17259620
49.

Lack of in vitro biofilm formation does not attenuate the virulence of Streptococcus gordonii in experimental endocarditis.

Bizzini A, Beggah-Möller S, Moreillon P, Entenza JM.

FEMS Immunol Med Microbiol. 2006 Dec;48(3):419-23. Epub 2006 Nov 7.

50.

Serological cross-reactivity between different Chlamydia-like organisms.

Casson N, Entenza JM, Greub G.

J Clin Microbiol. 2007 Jan;45(1):234-6. Epub 2006 Oct 25.

Supplemental Content

Loading ...
Support Center